Suggested remit: To appraise the clinical and cost effectiveness of capivasertib with fulvestrant within its marketing authorisation for treating hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer after endocrine treatment.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Further information In development
Process STA Standard
ID number 6370

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
01 March 2024 - 02 April 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6370
02 February 2024 Awaiting development
04 January 2024 In progress. DHSC referral received

For further information on our processes and methods, please see our CHTE processes and methods manual